Evogliptin tartrate is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus to improve glycemic control by enhancing insulin secretion and suppressing glucagon… Read more
Evogliptin tartrate is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus to improve glycemic control by enhancing insulin secretion and suppressing glucagon release. This category features high-quality reference standards essential for pharmaceutical analysis, including the active pharmaceutical ingredient and a selection of specific stereoisomeric impurities. These compounds serve as critical tools for researchers and analytical chemists engaged in impurity profiling, method validation, and routine quality control during the manufacturing process. By providing accurate characterization of known degradation products and potential synthesis by-products, these reference materials facilitate regulatory compliance and ensure the integrity of analytical testing protocols throughout the drug development lifecycle.